Breast cancer Archives - Medical Conferences

Spironolactone safe for androgenetic alopecia in cancer survivors

Presented By

Dr Chapman Wei, George Washington University, USA

Conference

AAD 2020

19 August, 2020 07:33

MRI and 14G biopsies are not accurate enough in pCR detection

Trial

MICRA

Conference

SABCS 2019

13 February, 2020 23:54

No higher pathologic complete response with atezolizumab added to chemotherapy

Trial

IMpassion130

Conference

SABCS 2019

13 February, 2020 23:54

Anastrozole yields long term effects in the prevention of breast cancer occurrence

Trial

IBIS-II

Conference

SABCS 2019

13 February, 2020 23:47

S-1 shows promising results in combination with endocrine therapy

Conference

SABCS 2019

13 February, 2020 23:40

Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer

Trial

APHINITY

Conference

SABCS 2019

13 February, 2020 23:13

Breast cancer incidence decreased by oestrogen alone but increased by adding progestin

Conference

SABCS 2019

13 February, 2020 22:59

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Trial

Phase 2, DESTINY-Breast01

Conference

SABCS 2019

13 February, 2020 22:54

Partial breast irradiation could be as effective as whole breast irradiation

Trial

Phase 3, APBI IMRT

Conference

SABCS 2019

13 February, 2020 22:48

Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer

Conference

SABCS 2019

13 February, 2020 22:42

Higher age means higher risk for breast cancer patients

Conference

SABCS 2019

13 February, 2020 22:15

Sensory peripheral neuropathy after taxane treatment is not uncommon

Conference

SABCS 2019

13 February, 2020 21:50

Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination

Trial

Phase 3, FeDeriCa

Conference

SABCS 2019

13 February, 2020 21:44

Palbociclib not statistically superior to capecitabine in PFS

Trial

Phase 3, PEARL

Conference

SABCS 2019

13 February, 2020 13:21

Residual cancer burden is a predictor for all-type breast cancer patients

Conference

SABCS 2019

13 February, 2020 12:11

Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients

Trial

MINDACT, TAILORx

Conference

SABCS 2019

13 February, 2020 10:01

Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer

Presented By

Dr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre

Trial

Phase 3, MONALEESA-7

Conference

ASCO 2019

15 July, 2019 15:00

Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer

Presented By

Dr Ian E. Krop, Dana-Farber Cancer Institute, USA

Trial

Phase 3, APHINITY

Conference

ASCO 2019

15 July, 2019 14:00

ImPassion130 brings breast cancer into the immunotherapy era

Trial

Phase 3, ImPassion130

Conference

ASCO 2019

15 July, 2019 11:27

Discordance of biomarkers in multifocal and lymph node positive breast cancer

Presented By

Dr Marie Sundquist, Kalmar County Hospital, Sweden

Conference

BCC 2019

21 May, 2019 23:51

Extrapolating data from clinical trials as we treat patients in real life

Presented By

Prof. Sharon Giordano, MD Anderson, Houston, USA

Trial

APHINITY, KATHERINE, ExteNET

Conference

BCC 2019

21 May, 2019 23:44

History of the consensus meeting

Conference

BCC 2019

21 May, 2019 23:08

New Prognostic Biomarkers for Survival Breast Cancer

Presented By

Dr Jasmin Zeindler, University Hospital Basel, Switzerland

Conference

BCC 2019

21 May, 2019 22:53

What is the clinical benefit of treatment of patients with early breast cancer?

Presented By

Prof. Ann Partridge, Dana-Farber Cancer Institute, Boston, USA

Conference

BCC 2019

21 May, 2019 22:47

Primary surgery: margins

Conference

BCC 2019

21 May, 2019 22:09

Skin and nipple sparing surgery: still a matter of debate

Conference

BCC 2019

21 May, 2019 21:11

Surgery of the axilla: indications decrease

Trial

AMAROS

Conference

BCC 2019

21 May, 2019 20:13

DCIS: de-escalation of (adjuvant) therapy

Conference

BCC 2019

21 May, 2019 19:14

Gene expression signatures

Trial

MINDACT, TAILOR-X, PLAN-B

Conference

BCC 2019

21 May, 2019 18:16

Neoadjuvant therapy and residual disease

Conference

BCC 2019

21 May, 2019 17:25

Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA

Trial

KATHERINE, CREATE-X

Conference

BCC 2019

21 May, 2019 16:29

Endocrine therapy in premenopausal patients

Trial

SOFT, TEXT

Conference

BCC 2019

21 May, 2019 15:30

Endocrine therapy in postmenopausal patients: a graded approach

Conference

BCC 2019

21 May, 2019 14:32

Adjuvant Her2-targeted therapy

Trial

APHINITY

Conference

BCC 2019

21 May, 2019 13:35

Adjuvant therapy in triple-negative breast cancer

Conference

BCC 2019

21 May, 2019 12:36

Bisphosphonates and denosumab

Trial

D-CARE

Conference

BCC 2019

21 May, 2019 11:38

Germ-line mutations

Conference

BCC 2019

21 May, 2019 10:39

Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer

Presented By

Dr Ariadna Gasol Cudos, Hospital Universitari Arnau de Vilanova de Lleida, Spain

Conference

BCC 2019

21 May, 2019 09:55

Adjuvant and neoadjuvant therapy: principles and practical considerations

Presented By

Prof. Eric Winer, Dana-Farber Cancer Institute, Boston, USA

Trial

NSABP B-18, NSABP B-27, ACOSOG Z1071, NEO-ALTTO, APHINITY, I-SPY2

Conference

BCC 2019

21 May, 2019 09:49

Pregnancy after breast cancer

Trial

POSITIVE, NCT02308085

Conference

BCC 2019

21 May, 2019 09:40

Life style

Conference

BCC 2019

21 May, 2019 08:41